title: Immunotherapy for patients with persistent allergic rhinitis unsatisfied with free chronic pharmacotherapy.
abstract: BACKGROUND
  Chronic pharmacotherapy is recommended to patients with persistent moderate-severe (PM-S) allergic rhinitis (AR). The cost of pharmacotherapy is the main barrier to achieve symptoms control.
  
  
  OBJECTIVE
  To determine the benefits of mite subcutaneous immunotherapy (SIT) in patients with PM-S AR not satisfied with chronic pharmacotherapy received free of charge.
  
  
  METHODS
  Open study with seven (7) patients with PM-S AR not satisfied with chronic pharmacotherapy. Prior to enrollment patients had received monthly for more than five months and free of charge, optimal pharmacotherapy. We compared, off pharmacotherapy, symptoms and quality of life (QOL) before and during SIT.
  
  
  RESULTS
  Mite SIT improved nasal symptoms, non nasal symptoms and QOL. Off pharmacotherapy patients reported adequate control of symptoms and were satisfied.
  
  
  CONCLUSIONS
  Not all patients with PM-S AR are satisfied with chronic pharmacotherapy, even if medication is received free of charge. SIT control symptoms and satisfies patients with PM-S AR unsatisfied with free chronic pharmacotherapy.
authors.affiliation: Allergy and Immunology. Clínica Ricardo Palma, Lima, Perú. geredaj@hotmail.com
authors.forename: José E Gereda
authors.initials: JE
authors.lastname: Solari
authors.forename: Juan
authors.initials: J
authors.lastname: Loo
authors.forename: Antonio
authors.initials: A
authors.lastname: Felices
authors.forename: Jorge
authors.initials: J
authors.lastname: Casas
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D018926:Anti-Allergic Agents / Q000191:economics / Q000627:therapeutic use; D039741:Antigens, Dermatophagoides / Q000627:therapeutic use; D019819:Budesonide / Q000191:economics / Q000627:therapeutic use; D017332:Cetirizine / Q000191:economics / Q000627:therapeutic use; D003888:Desensitization, Immunologic / Q000191:economics; D016527:Drug Costs; D005260:Female; D006801:Humans; D007182:Income; D019458:Insurance Coverage; D007356:Insurance, Pharmaceutical Services; D017336:Loratadine / Q000191:economics / Q000627:therapeutic use; D008297:Male; D000068656:Mometasone Furoate; D017060:Patient Satisfaction; D011244:Pregnadienediols / Q000191:economics / Q000627:therapeutic use; D011446:Prospective Studies; D039981:Pyroglyphidae / Q000276:immunology; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy / Q000628:therapy*; D011795:Surveys and Questionnaires
chemical_list: D018926:Anti-Allergic Agents; D039741:Antigens, Dermatophagoides; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D019819:Budesonide; D017336:Loratadine; D017332:Cetirizine